Status:
TERMINATED
Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept
Lead Sponsor:
Emory University
Conditions:
Cardiac Transplantation
Eligibility:
All Genders
2-18 years
Phase:
NA
Brief Summary
The survival of children who have received heart transplants has greatly improved over the last ten years. One reason for this is better control over rejection. Rejection medications require a delicat...
Detailed Description
Pediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care they receive hi...
Eligibility Criteria
Inclusion
- Heart Transplant Recipients who are transplanted during the course of this study.
- Age 2 weeks to 18 years
- Receiving or plan to receive Mycophenolate mofetil therapy
- Patient/Family has signed an informed assent/consent
Exclusion
- Patients that are unable to follow protocol schedule of assessment
- Patients with chronic autoimmune disease
- Patients who have received a multiple organ transplant (i.e. heart-liver, heart-lung etc.)
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00166153
Start Date
January 1 2003
End Date
May 1 2005
Last Update
November 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322